Hyperion DeFi (NASDAQ:HYPD) versus Sentage (NASDAQ:SNTG) Head-To-Head Contrast

Sentage (NASDAQ:SNTG) and Hyperion DeFi (NASDAQ:HYPD) are both small-cap finance companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Institutional & Insider Ownership

0.1% of Sentage shares are held by institutional investors. Comparatively, 25.8% of Hyperion DeFi shares are held by institutional investors. 62.4% of Sentage shares are held by company insiders. Comparatively, 7.5% of Hyperion DeFi shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations and price targets for Sentage and Hyperion DeFi, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sentage	1	0	0	0	1.00
Hyperion DeFi	2	0	2	0	2.00

Hyperion DeFi has a consensus price target of $7.20, indicating a potential upside of 118.18%. Given Hyperion DeFi’s stronger consensus rating and higher possible upside, analysts plainly believe Hyperion DeFi is more favorable than Sentage.

Profitability

This table compares Sentage and Hyperion DeFi’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sentage	N/A	N/A	N/A
Hyperion DeFi	416.56%	-11.62%	-9.96%

Earnings and Valuation

This table compares Sentage and Hyperion DeFi”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sentage	$70,000.00	68.24	-$2.28 million	N/A	N/A
Hyperion DeFi	$810,000.00	63.31	-$45.31 million	($6.53)	-0.51

Sentage has higher earnings, but lower revenue than Hyperion DeFi.

Volatility and Risk

Sentage has a beta of 2.43, suggesting that its stock price is 143% more volatile than the S&P 500. Comparatively, Hyperion DeFi has a beta of 2.53, suggesting that its stock price is 153% more volatile than the S&P 500.

Summary

Hyperion DeFi beats Sentage on 7 of the 12 factors compared between the two stocks.

About Sentage

Sentage Holdings Inc. provides a range of financial services. The company offers consumer loan repayment and collection management, loan recommendation, and prepaid payment network services in China. It also provides consultancy and information technology support services. Sentage Holdings Inc. was incorporated in 2019 and is headquartered in Shanghai, the People's Republic of China.

About Hyperion DeFi

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.